Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Arbutus to Participate in October Investor Conferences

GlobeNewswire September 28, 2021

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

GlobeNewswire September 21, 2021

Arbutus to Participate in Upcoming Investor Conferences

GlobeNewswire September 7, 2021

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2021

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 3, 2021

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire July 29, 2021

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

GlobeNewswire July 7, 2021

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

GlobeNewswire July 6, 2021

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

GlobeNewswire June 29, 2021

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress(TM) 2021 - All Selected for Best of ILC(TM)

GlobeNewswire June 26, 2021

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

GlobeNewswire June 2, 2021

Arbutus to Participate in Upcoming Investor Conferences

GlobeNewswire May 26, 2021

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 5, 2021

Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

Canada NewsWire May 3, 2021

Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire April 28, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

GlobeNewswire April 1, 2021

Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

GlobeNewswire March 16, 2021

Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 4, 2021

Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

GlobeNewswire February 26, 2021